This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David N. Osser, MD; Lawrence G. Albert, MD
Massachusetts Mental Health Center 74 Fenwood Rd Boston, MA 02115 and Taunton Hospital and Regional Service Center Box 151 Taunton, MA 02780

Arch Gen Psychiatry. 1990;47(2):189.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

As Marder and Van Putten¹ have commented, the impressive results of the Kane et al² multicenter trial of clozapine still leave some questions unanswered about who should receive a trial of this medication. They point out that it is unclear how the large group of partial ("suboptimal") responders to standard neuroleptics would respond to clozapine. The response in this subgroup of treatment-resistant schizophrenics has not been compared with that of nonresponders, yet it would be of interest since these pattern differences may be presumed to reflect differences in how the brain responds to challenge with a standard medication and, by inference, important differences in how these brains are disordered.³

Kolakowska et al⁴ and Kolakowska⁵ have found in prospective and retrospective studies that these patterns of drug response (good, partial, and poor) are generally stable over the course of the illness of schizophrenic . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?